Aditxt (Nasdaq: ADTX), a company dedicated to discovering, developing, and deploying promising health innovations, announced the acquisition of a portfolio of EEG brain monitoring technologies and devices formerly owned by Brain Scientific, Inc. The products targeting the neurology monitoring market will be essential in shaping its dynamic landscape for neurological care.

bioAffinity Technologies (Nasdaq: BIAF), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer and lung disease, provided a summary of recent Company news.

Genetic Technologies Limited (Nasdaq: GENE), a company at the forefront in personalized predictive genomics, reshaping the healthcare landscape with its inventive strategy for early disease detection and personalized wellness, shared a business update for the second quarter of fiscal year 2024 ended December 31, 2023.

BullFrog AI (Nasdaq: BFRG), a technology-enabled drug development company using artificial intelligence (AI) and machine learning to enable the successful development of pharmaceuticals and biologics, announced the pricing of an underwritten public offering of an aggregate of 1,507,139 shares of common stock (or pre-funded warrants (“Pre-Funded Warrants”) in lieu thereof) and accompanying warrants to purchase 1,507,139 shares of common stock at a public offering price of $3.782 per share (inclusive of the Pre-Funded Warrant exercise price) for gross proceeds of approximately $5,700,000, prior to deducting underwriting discounts and offering expenses.